Wesbanco Bank Inc. Lowers Holdings in Gilead Sciences, Inc. $GILD

Wesbanco Bank Inc. reduced its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 17.4% during the third quarter, HoldingsChannel reports. The fund owned 20,464 shares of the biopharmaceutical company’s stock after selling 4,321 shares during the period. Wesbanco Bank Inc.’s holdings in Gilead Sciences were worth $2,272,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of GILD. Vanguard Group Inc. grew its position in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC raised its holdings in Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after buying an additional 727,515 shares during the last quarter. Norges Bank bought a new position in shares of Gilead Sciences in the second quarter worth approximately $2,150,268,000. Invesco Ltd. grew its holdings in shares of Gilead Sciences by 33.5% during the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after buying an additional 3,394,330 shares during the last quarter. Finally, Amundi increased its position in shares of Gilead Sciences by 18.2% during the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock valued at $1,167,221,000 after acquiring an additional 1,614,355 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q4 results beat: Gilead reported EPS of $1.86 and revenue of ~$7.9B, topping consensus and driven by strong HIV and liver‑disease sales. Gilead Sciences Inc (GILD) Q4 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth …
• Positive Sentiment: Dividend raised: Board approved a 3.8% increase to $0.82 quarterly ($0.82 payable Mar 30; ex‑div Mar 13), supporting income investors (yield ~2.2%). Gilead Sciences Announces 3.8-Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Pipeline and launches: Management highlighted Yeztugo launch momentum and possible approvals later this year (two cancer therapies plus an additional HIV option), which could drive future growth. Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Full Q4 call transcript now available for detail on revenue mix and margin drivers — useful for investors digging into product‑level trends. Gilead Sciences, Inc. (GILD) Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Analysts’ metric review: Several outlets note Gilead beat top‑ and bottom‑line estimates but some year‑over‑year metrics are mixed — monitor product mix and FX effects in the slides. Gilead (GILD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Negative Sentiment: Guidance disappointed: FY‑2026 EPS guidance of $8.45–8.85 and revenue $29.6–30.0B sit at or below consensus (EPS ~8.69; revenue ~30.1B), prompting the after‑hours selloff. Expect near‑term pressure until guidance proves conservative or growth catalysts materialize. Gilead 2026 outlook short of Wall Street view, shares dip

Analyst Ratings Changes

Several analysts have commented on the company. TD Cowen increased their target price on Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research note on Thursday, January 29th. BMO Capital Markets upped their price target on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a report on Monday, January 26th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Thursday, January 8th. Scotiabank began coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 target price on the stock. Finally, Argus raised their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.88.

Gilead Sciences Stock Down 2.9%

GILD stock opened at $147.23 on Wednesday. The company has a market cap of $182.67 billion, a price-to-earnings ratio of 22.83, a P/E/G ratio of 0.80 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The business’s 50-day moving average is $128.39 and its two-hundred day moving average is $121.53. Gilead Sciences, Inc. has a fifty-two week low of $93.37 and a fifty-two week high of $153.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. During the same quarter in the prior year, the firm earned $1.90 EPS. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be given a $0.82 dividend. The ex-dividend date is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s payout ratio is 48.99%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer owned 150,503 shares of the company’s stock, valued at $18,709,027.93. The trade was a 1.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This trade represents a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 319,391 shares of company stock worth $44,141,101. 0.27% of the stock is owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.